

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C12N 15/10, 15/11, 15/29, 15/52, 15/82, A01H 5/00</b></p>	<p><b>A1</b></p>	<p>(11) International Publication Number: <b>WO 96/13582</b>  (43) International Publication Date: <b>9 May 1996 (09.05.96)</b></p>
<p>(21) International Application Number: <b>PCT/US95/13918</b>  (22) International Filing Date: <b>23 October 1995 (23.10.95)</b>  (30) Priority Data: <b>08/329,603      26 October 1994 (26.10.94)      US</b>  (71) Applicant: <b>DNA PLANT TECHNOLOGY CORPORATION</b> <b>[US/US]; 6701 San Pablo Avenue, Oakland, CA 94608</b> <b>(US).</b>  (72) Inventors: <b>JAMES, Douglas, W., Jr.; 2131 Prince Street,</b> <b>Berkeley, CA 94705 (US). LIM, Eda; 53 Parker Avenue,</b> <b>Atherton, CA 94027 (US). KELLER, Janis; 21423 Tan-</b> <b>glewood Drive, Castro Valley, CA 94546 (US). DOONER,</b> <b>Hugo, K.; 2011 Blackwood Drive, Walnut Creek, CA 94596</b> <b>(US).</b>  (74) Agents: <b>BASTIAN, Kevin, L. et al.; Townsend and Townsend</b> <b>and Crew, Steuart Street Tower, One Market, San Francisco,</b> <b>CA 94105-1492 (US).</b></p>		<p>(81) Designated States: <b>AU, CA, European patent (AT, BE, CH,</b> <b>DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</b>  <b>Published</b> <i>With international search report.</i></p>
<p>(54) Title: <b>FAEI GENES AND THEIR USES</b>  (57) Abstract  The present invention provides polynucleotide sequences from <i>FAEI</i> genes. <i>FAEI</i> genes encode elongation enzymes which catalyze</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

## FAE1 GENES AND THEIR USES

5

### BACKGROUND OF THE INVENTION

The present invention relates to plant molecular biology. In particular, it provides compositions and methods useful for modulating fatty acid synthesis in plants.

Fatty acids (FAs) are the major constituents of acyl lipids in plant tissues. Acyl lipids are mainly present as triacylglycerols in the oil bodies of tissues which serve as food storage, such as seeds and the fleshy parts of fruits. These tissues are important commercial sources of fats and oils. Fatty acids are also found as glycolipids and phospholipids in other tissues, such as leaves, roots, or shoots, where they are integral components of the various cell membranes.

15

The principal FAs are saturated or unsaturated monocarboxylic acids with an unbranched even-numbered carbon chain. The main saturated FAs are lauric (12:0, i.e., C12 chain with no double bonds), myristic (14:0), palmitic (16:0), and stearic (18:0). The main unsaturated FAs are oleic (18:1), linoleic (18:2) and linolenic (18:3). Seed storage lipids accumulate mostly 16- and 18-carbon FAs. Oilseeds of the *Cruciferae* and a few other plants also accumulate C20 and C22 FAs, collectively referred to as very long chain fatty acids (VLCFAs) because of their relatively longer chain length compared to the more common FAs found in plants (*see, in general*, Stumpf, in *Biochemistry of Plants*, Vol. 9, Stumpf ed., Academic Press, New York, 1987) and Browse and Somerville, *Ann. Rev. Plant Physiol. Plant Mol. Biol.* 42:467-506 (1991).

25

The presence of VLCFAs in vegetable oils markedly affects their use. For example, erucic acid (22:1) has detrimental nutritional effects and, thus, is undesirable in edible oils. Rapeseed oil is naturally high in erucic acid, but through a concerted breeding effort, canola lines that are almost devoid of erucic acid have been developed (Loof and Appleqvist, in *Rapeseed*, Appleqvist and Ohlson, eds. Elsevier Publishing, 1972). On the other hand, vegetable oils high in erucic acid have found many industrial uses, including use as diesel fuel and as a raw material for an array of products.

30

including paints, corrosion inhibitors, cosmetics, plastics, pharmaceuticals, and lubricants (Murphy, *Tibtech* 10:84-87 (1992)).

The biosynthesis of saturated FAs having a carbon chain up to C18 proceeds in the chloroplast via the sequential condensation of C2 units from acyl thioesters. FA synthesis is initiated by the condensation of acetyl CoA and malonyl ACP, catalyzed by the recently discovered enzyme  $\beta$ -ketoacyl synthase III (KASIII) (Jaworski *et al.*, *Plant Physiol.* 90:41-44 (1989)). The enzyme ketoacyl synthase I is required for the elongation of saturated acyl-ACP from C4 to C16. The last elongation step in the chloroplast, from C16 to C18, is catalyzed by ketoacyl synthase II. Each condensation is followed by three enzymatic steps, which involve reduction and dehydration of the  $\beta$ -ketoacyl derivative formed by the synthase and reduction of the double bond in the corresponding enoyl-ACP intermediate (Stumpf, 1987, *supra*).

Elongation of the FA carbon chain from C18 to C22 occurs outside the chloroplast by the sequential addition of two C2 moieties from malonyl CoA to a C18 carbon skeleton, a reaction catalyzed by a particulate acyl CoA elongase complex (Stumpf and Pollard, in *High and Low Erucic Acid Rapeseed Oils*, Kramer *et al.* eds. Academic Press, 1983). Whether the two elongation reactions are carried out by one or two different enzyme complexes is not clear (Taylor *et al.*, *Plant Physiol.* 99:1609-1618 (1992)). The same four reactions described above for the biosynthesis of C18 FAs are involved in the further elongation of C18 in plants: (i) condensation of 18:1 CoA with malonyl CoA to form a  $\beta$ -ketoacyl derivative, (ii) reduction and (iii) dehydration of the  $\beta$ -ketoacyl derivative, and (iv) reduction of the double bond (Creach and Lessire *JAOC* 70:1129-133(1993)). However, because of the difficulties in solubilizing membrane-bound enzymes, the elongase complex has not been well characterized. Elongases have been partially purified from several plants, including *Allium porrum* or leek (Bessoule *et al.*, *Arch. Biochem. Biophys.* 268:475-484 (1989)), *Lunaria annua* or honesty (Fehling *et al.*, *Biochim. Biophys. Acta* 1126:88-94 (1992)), and *Brassica napus* or rapeseed (Creach and Lessire, 1993, *supra*).

In *Arabidopsis*, mutations in a gene associated with fatty acid elongation, the *FAEI* gene, result in a deficiency in acyl chain elongation activities from C18 to C20 and C20 to C22, and in highly reduced levels of seed VLCFAs (James and Dooner, *Theor. Appl. Genet.* 80:241-245 (1990); Lemieux *et al.*, *Theor. Appl. Genet.* 80:234-240

(1990); James and Dooner *Theor. Appl. Genet.* 82:409-412 (1991); and Kunst *et al. Plant Physiol. Biochem.* 30:425-4343 (1992)).

FA biosynthetic genes have been isolated by the conventional biochemical approaches of purifying the corresponding enzyme in order to generate antibodies or  
5 oligonucleotides with which to probe cDNA libraries. Among them are genes for ACP (Schmid and Ohlrogge, *Plant Mol. Biol.* 15:765-778 (1990)), KASII (International Publications WO92/03564 and WO93/10240), KASIII (Tai and Jaworski, *Plant Physiol.* 103L1361-1367 (1993)), stearoyl-ACP desaturase (International Publication No. WO91/18985), acyl-ACP thioesterases (U.S. Patent No. 5,298,421) enoyl-ACP reductase  
10 (Kater *et al.*, *Plant Molec. Biol.* 17:895-909 (1991)), 3-ketoacyl-ACP reductase (Klein *et al.*, *Mol. Gen. Genet.* 233:122-128 (1992)), acyl-ACP:glycerol-3-P acyl transferase (Weber *et al.*, *Plant Molec. Biol.* 17:1067-1076 (1991)). Others have been isolated on the basis of DNA homology to previously cloned genes from related species. e.g., genes for stearoyl-ACP desaturases (Knutzon *et al.*, *Proc. Natl. Acad. Sci. USA* 89:2624-2628  
15 (1992)) or acyl-ACP:glycerol-3-P acyl transferases (Nishida *et al.*, *Plant Molec. Biol.* 21:267-277 (1993)).

Genes encoding FA biosynthetic enzymes in *Arabidopsis* have also been isolated. Examples include the *FAD3* gene encoding an endoplasmic reticulum (ER) 18:2 desaturase (Arondel *et al.*, *Science* 258:1353-1354 (1992)), *FAD3* (Yadav *et al.*, *Plant Physiol.* 103:467-476 (1993)), and the *FAD2* gene, which encodes another ER enzyme,  
20 an 18:1 desaturase (Okuley *et al. The Plant Cell*, 6:147-158 (1994)).

There have been no reports of the isolation of *FAEI* genes. Isolation of these genes would be particularly useful in modulating fatty acid synthesis in plants. These and other advantages are provided by the present invention.

25

### SUMMARY OF THE INVENTION

The present invention provides isolated DNA constructs comprising a polynucleotide sequence from an *FAEI* gene. *FAEI* genes encode elongation enzymes which catalyze the conversion of C18 FAs to C20-C22 FAs. A preferred embodiment of  
30 the genes of the invention comprises sequences substantially identical to sequences which are, which contain, or which are contained within, SEQ. ID. No. 1.

DNA constructs comprising the polynucleotides of the invention are used to modify *FAEI* gene expression and thereby modulate FA content in plant organs or

parts, particularly seeds. Thus, a DNA construct of the invention may further comprise a promoter operably linked to the polynucleotide sequence. The promoter is preferably a plant promoter such as a seed-specific promoter. If suppression of an endogenous *FAEI* gene is desired, the polynucleotide sequence may be linked to the promoter in the sense or antisense orientations.

5 The invention also provides transgenic plants (e.g., *Brassica* plants) comprising a recombinant expression cassette which includes a plant promoter operably linked to the polynucleotide sequence. The transgenic plants exhibit altered FA content in one or more tissues. For use in plants which produce edible oils, the introduction of the recombinant expression cassettes preferably results in inhibition of an endogenous *FAEI* gene, resulting in plants with decreased VLCFA content.

10 The invention further provides a method of altering FA content in a plant. The method comprises introducing into plant tissue a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence from an *FAEI* gene, in the sense or the antisense orientation. The promoter may be a tissue-specific promoter, e.g., a seed-specific promoter. The expression cassette is typically introduced into the plant tissue using *Agrobacterium* or other standard means. The transformed plant tissue is regenerated into whole plants, whereby normally the regenerated plant transcribes the introduced polynucleotide sequence. The plants are then assayed and selected for altered FA content.

15 20 The invention further provides methods of isolating an *FAEI* gene from a plant. The method may comprise probing a DNA library (e.g., a cDNA library) prepared from the plant with oligonucleotide probes comprising a polynucleotide sequence from an *FAEI* gene.

25

#### Definitions

The phrase "nucleic acid sequence" refers to a single or double-stranded polymer of deoxyrib nucleotide or ribonucleotide bases read from the 5' to the 3' end. It includes self-replicating plasmids, infectious polymers of DNA or RNA and non-functional DNA or RNA.

30

The term "promoter" refers to a region of DNA upstream from the start of transcription, containing the initiation and binding of RNA polymerase and other

proteins to initiate transcription. A "plant promoter" is a promoter capable of initiating transcription in plant cells.

The term "plant" includes whole plants, plant organs (e.g., leaves, stems, roots, etc.), seeds and plant cells and progeny of same. The class of plants which can be used in the method of the invention is generally as broad as the class of higher plants amenable to transformation techniques, including both monocotyledonous and dicotyledonous plants, as well as certain lower plants such as algae. It includes plants of a variety of ploidy levels, including polyploid, diploid and haploid.

A "heterologous sequence" is one that originates from a foreign species, or, if from the same species, is substantially modified from its original form. For example, a heterologous promoter operably linked to a structural gene is from a species different from that from which the structural gene was derived, or, if from the same species, is substantially modified from its original form.

As used herein an "*FAEI* gene" is a gene encoding an enzyme, or a component of an enzyme, that catalyzes the conversion of oleic acid (18:1) to eicosenoic acid (20:1) and eicosenoic acid to erucic acid (22:1).

As used herein, a homolog of a particular *FAEI* gene (e.g., SEQ. ID. No. 1) is a second gene in the same plant type or in a different plant type, which has a polynucleotide sequence of at least 50 contiguous nucleotides which are substantially identical (determined as described below) to a sequence in the first gene. It is believed that, in general, homologs share a common evolutionary past.

A "polynucleotide sequence from an *FAEI* gene" is a subsequence or full length polynucleotide sequence of an *FAEI* gene which, when present in a transgenic plant, has the desired effect, for example, inhibiting expression of the endogenous *FAEI* gene. In the case of both expression of transgenes and inhibition of endogenous genes (e.g., by antisense, or sense suppression) one of skill will recognize that the inserted polynucleotide sequence need not be identical and may be "substantially identical" to a sequence of the gene from which it was derived. As explained below, these variants are specifically covered by this term.

In the case where the inserted polynucleotide sequence is transcribed and translated to produce a functional polypeptide, one of skill will recognize that because of codon degeneracy a number of polynucleotide sequences will encode the same polypeptide. These variants are specifically covered by the term "polynucleotide

sequence from an *FAEI* gene". In addition, the term specifically includes those full length sequences substantially identical (determined as described below) with an *FAEI* gene sequence and that encode proteins that retain the function of the *FAEI* enzyme. Thus, the above term includes variant polynucleotide sequences which have substantial  
5 identity with the sequences disclosed here and which encode enzymes capable of catalyzing the same reactions described above.

In the case of polynucleotides used to inhibit expression of an endogenous gene, the introduced sequence also need not be perfectly identical to a sequence of the target endogenous gene. The introduced polynucleotide sequence will typically be at  
10 least substantially identical (as determined below) to the target endogenous sequence.

Two nucleic acid sequences or polypeptides are said to be "identical" if the sequence of nucleotides or amino acid residues, respectively, in the two sequences is the same when aligned for maximum correspondence as described below. The term "complementary to" is used herein to mean that the complementary sequence is identical  
15 to all or a portion of a reference polynucleotide sequence.

Sequence comparisons between two (or more) polynucleotides or polypeptides are typically performed by comparing sequences of the two sequences over a "comparison window" to identify and compare local regions of sequence similarity. A "comparison window", as used herein, refers to a segment of at least about 20  
20 contiguous positions, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned.

Optimal alignment of sequences for comparison may be conducted by the local homology algorithm of Smith and Waterman *Adv. Appl. Math.* 2: 482 (1981), by  
25 the homology alignment algorithm of Needleman and Wunsch *J. Mol. Biol.* 48:443 (1970), by the search for similarity method of Pearson and Lipman *Proc. Natl. Acad. Sci. (U.S.A.)* 85: 2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, WI), or by inspection.

"Percentage of sequence identity" is determined by comparing two  
30 optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide sequence in the comparison window may comprise additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or



deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity.

The term "substantial identity" of polynucleotide sequences means that a polynucleotide comprises a sequence that has at least 60% sequence identity, preferably at least 80%, more preferably at least 90% and most preferably at least 95%, compared to a reference sequence using the programs described above (preferably BESTFIT) using standard parameters. One of skill will recognize that these values can be appropriately adjusted to determine corresponding identity of proteins encoded by two nucleotide sequences by taking into account codon degeneracy, amino acid similarity, reading frame positioning and the like. Substantial identity of amino acid sequences for these purposes normally means sequence identity of at least 40%, preferably at least 60%, more preferably at least 90%, and most preferably at least 95%.

Another indication that nucleotide sequences are substantially identical is if two molecules hybridize to each other under stringent conditions. Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5° C lower than the thermal melting point (T<sub>m</sub>) for the specific sequence at a defined ionic strength and pH. The T<sub>m</sub> is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Typically, stringent conditions will be those in which the salt concentration is about 0.02 molar at pH 7 and the temperature is at least about 60°C.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is an illustration of the strategy used to isolate FA biosynthetic genes from *Arabidopsis*.

Figure 2 shows a comparison of the nucleotide sequence of *FAEI* around the site of insertion of the transposable element *Ac*.

Figure 3 is a diagram of the structure of the *FAEI* genomic region, including the location of the cDNA and of the *Ac* insertion site in *fael-m1(Ac)*.

Figure 4 is a comparison of the amino acid sequences of SEQ. ID. No. 2 and SEQ. ID. No. 4 using the BESTFIT sequence comparison program.

#### DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The present invention provides compositions and methods for regulating fatty acid synthesis in plants. The effect of one enzyme, FAE1, on FA synthesis in *Arabidopsis* has been elucidated by studying mutants of the gene encoding the enzyme. As noted above, a mutant deficient in the elongation of oleate (18:1) and showing only 0.2% eicosenoic acid in its seed oil was described by James and Dooner *Theor. Appl. Genet.* 80:241-245 (1991) and Lemieux *et al. Theor. Appl. Genet.* 80:234-240 (1990).  
10 Based on segregation of this trait, James and Dooner and Lemieux *et al.* determined that it is caused by a single nuclear mutation in a gene that the latter authors designated as *FAE1*.

The present invention provides cloned genes encoding the FAE1 enzyme. *FAE1* genes useful in the present invention include an *FAE1* gene identified in  
15 *Arabidopsis* as well as homologs in other plants (either of the same or different genus or species). The present invention also provides recombinant vectors comprising polynucleotide sequences from an *FAE1* gene which can be used in variety of ways.

Generally, the invention has use in modulating FA content in all higher  
20 plants. The invention thus has use over a broad range of types of plants, including species from the genera *Fragaria*, *Lotus*, *Medicago*, *Onobrychis*, *Trifolium*, *Trigonella*, *Vigna*, *Citrus*, *Linum*, *Geranium*, *Manihot*, *Daucus*, *Arabidopsis*, *Brassica*, *Raphanus*, *Sinapis*, *Atropa*, *Capsicum*, *Hyoscyamus*, *Lycopersicon*, *Nicotiana*, *Solanum*, *Petunia*, *Digitalis*, *Majorana*, *Cichorium*, *Helianthus*, *Lactuca*, *Bromus*, *Asparagus*, *Antirrhinum*,  
25 *Heterocallis*, *Nemesia*, *Pelargonium*, *Panicum*, *Pennisetum*, *Ranunculus*, *Senecio*, *Salpiglossis*, *Cucumis*, *Browallia*, *Glycine*, *Lolium*, *Zea*, *Triticum*, *Sorghum*, and *Datura*.

More specifically, plants for which the invention may be used in modifying FA content include oil crops of the *Cruciferae* family: canola, rapeseed (*Brassica* spp.), crambe (*Crambe* spp.), honesty (*Lunaria* spp.) lesquerella (*Lesquerella* spp.) and others; the *Compositae* family :sunflower (*Helianthus* spp.), safflower (*Carthamus* spp.), niger (*Guizotia* spp.) and others; the *Palmae* family: palm (*Elaeis* spp.), coconut (*Cocos* spp.) and others; the *Leguminosae* family: peanut (*Arachis* spp.), soybean (*Glycine* spp.) and others; and plants of other families such as maize (*Zea* spp.).  
30

cotton (*Gossypium* sp.), jojoba (*Simonsia* sp.), flax (*Linum* sp.), sesame (*Sesamum* spp.), castor bean (*Ricinus* spp.), olive (*Olea* spp.), poppy (*Papaver* spp.), spurge (*Euphorbia*, spp.) meadowfoam (*Limnanthes* spp.) and cuphea (*Cuphea* spp.).

As noted above, VLCFAs, in particular erucic acid, have detrimental nutritional effects and, thus, are undesirable in edible oils. Using standard techniques in plant molecular biology as described below, the production of erucic acid can be decreased in plants used for the production of edible oils, in particular rape, *Brassica napus*.

Alternatively, vegetable oils high in VLCFAs, particularly erucic acid, have many industrial uses. Thus, the invention can be used to increase VLCFA content of plant oils by over-expression of *FAEI*. In addition, alcohols derived from the VLCFAs by reduction of the carboxyl group will also increase in these plants. VLCF alcohols are esterified with VLCFAs in jojoba oil, and can be used as a substitute for sperm whale oil in high quality lubricants and a valuable carrier for medicines. For instance, crambe and jojoba, two sources of industrial oils valued for their VLCFA content, can be modified to increase production of these FAs. The C20-C22 FA content of Crambe seed oil is about 50-60% 22:1 (Salunkhe and Desai, in *Postharvest Biotechnology of Oilseeds* pp 187-197 (CRC Press, Boca Raton, FL, 1986)) and jojoba seed wax, currently, about 54% 20:1+22:1 (Salunkhe and Desai, *supra*), could be increased by over-expression of *FAEI*.

The polynucleotides of the invention can also be used to modify other desirable traits in plants. For instance, since the constitution of leaf surfaces affects their permeability, by changing the composition of the FAs that make up the leaf (surface) cuticular waxes, the drought tolerance of plants can be affected. Thus, any trait in which VLCFA synthesis is important can be altered using the methods of the invention.

#### FAEI polypeptides

The enzymes of the invention share homology with those of two other condensing enzymes that utilize malonyl CoA, chalcone synthase (CHS) and stilbene synthase (STS). A consensus sequence among the three enzymes was revealed from a comparison of their amino acid sequences performed with the GCG computer programs (Devereux *et al.*, *Nuc. Acids. Res.* 12:387-395 (1984)). It consists of 17 amino acids spread over a 50 amino acid region close to the carboxyl end of the proteins (starting at

position 392 in *FAE1*). This region is just upstream of the CHS-STS 12 amino acid "signature sequence" (Fliegmann *et al.*, *Plant Mol. Biol.* 18:489-503 (1992)), which does not occur in the proteins of the invention.

The *FAE1* protein also shares homology with a conserved region in CHS and STS which is close to the active site cysteine identified by Lanz *et al.*, *J. Biol. Chem.* 266:9971-9976 (1991)). However, this region of homology {L-A-K-D-L-X(9)-L-V-V} does not overlap with the consensus sequence for the CHS/STS active site {G-C-(FY)-(GA)-G-G-T-X(2)-R}, but lies immediately next to its carboxyl end.

The amino acid sequence of the proteins of the invention is also homologous to the ketoacyl synthase (KAS) III enzyme of *E. coli* and spinach, the condensing enzyme that initiates FA biosynthesis in bacteria and plants by coupling acetyl CoA to malonyl ACP. In particular, the *FAE1* protein disclosed here is 35% identical and 47% similar to the *E. coli* KASIII (encoded by the *fabH* gene), and 32% identical and 46% similar to a KASIII from spinach over a 57 amino acid stretch that also starts at position 392 of *FAE1*.

The *FAE1* enzymes of the present invention preferably possess catalytic activity which is substantially equal to or higher than the activity of the protein set forth in SEQ. ID. No. 2. The polypeptides of the present invention may be natural, i.e., including an entire native *FAE1* enzyme isolated and purified from a natural source, or may be synthetic. Such natural *FAE1* polypeptides may be isolated from plant material, using methods described in the scientific literature which has been referenced above. By "isolated," it is meant that the *FAE1* proteins have been removed from their native environment, such as the plant tissue where they normally occur. Thus, the term "isolated" is meant to include the presence of a *FAE1* polypeptide as a heterologous component of a cell or other system, such as a microorganism expression host or a transformed higher plant. For example, the *FAE1* polypeptide of the present invention may be expressed in a microorganism host, such as bacteria or yeast, transformed or transfected with a DNA construct which encodes the polypeptide. Usually, such expression in microorganism hosts will be a first step in producing a "purified" *FAE1* polypeptide. Alternatively, "isolated" *FAE1* polypeptides may be expressed in transformed higher plants, where the *FAE1* polypeptides will frequently not be subjected to any form of purification. Such polypeptides, however, will be isolated in the sense that they have been removed from their native environment, frequently being the result

of expression of a heterologous gene, although in some cases being the result of expression of a homologous gene under the control of a heterologous promoter. In the latter case, the homologous FAE1 polypeptide may be expressed in plant tissues and at times other than would normally be the case.

5 FAE1 polypeptides may be isolated and purified from any natural source possessing significant amounts of a natural or native FAE1 enzyme. Isolation and purification may be obtained by conventional chemical purification techniques, such as liquid chromatography, affinity chromatography, gradient centrifugation, gel electrophoresis, size exclusion chromatography, ion exchange chromatography, hydrophobic interaction chromatography, reversed-phase chromatography, and the like. 10 Such techniques are well described in the scientific and patent literature. See, for example, Scopes, *Protein Purification*, Springer-Verlag, New York (1982). Such techniques are suitable for isolation of FAE1 polypeptides both from natural cellular sources and from recombinantly modified expression hosts.

15 The FAE1 enzymes of the present invention may be obtained in a substantially pure form. By "substantially pure," it is meant that the polypeptide will be present in an intermediate or final composition and a purity of at least about 50%, based on the weight of FAE1 polypeptide present in the total weight of the composition (weight/weight; w/w), and will be substantially free from interfering proteins and 20 contaminants, particularly proteins and contaminants which interfere with the desired catalytic activity and/or which are toxic, immunogenic, or which otherwise prevent the desired use of a final product. Preferably, the FAE1 polypeptides will be isolated or synthesized in a purity of at least about 60% w/w, more preferably at least about 70% w/w, and most preferably at least about 80% w/w. Often, even higher levels of purity 25 may be obtained, with 90% w/w, 95% w/w, or higher usually being achievable. Very high levels of purity, typically above 98% w/w and most preferably above 99% w/w, can also be obtained.

Synthetic FAE1 polypeptides according to the present invention may be produced by either of two general approaches. First, polypeptides having fewer than 30 about 200 amino acids, usually fewer than about 150 amino acids, and preferably fewer than about 100 amino acids, may be synthesized, e.g., by the well known Merrifield solid-phase method where amino acids are sequentially added to a growing chain (Merrifield (1963) *J. Am. Chem. Soc.* 85:2149-2156). Commercial systems employing

such solid phase techniques for the automated synthesis of polypeptides are available from vendors, such as Applied Biosystems, Inc., Foster City, California.

The second and generally preferred method for synthesizing FAE1 polypeptides according to the present invention involves the expression in cultured cells of recombinant DNA molecules encoding all or a desired portion of a FAE1 protein. The recombinant DNA molecule may incorporate either a natural or synthetic gene, with natural genes and cDNA being obtainable from plant seed material by conventional methods, as described in the literature cited above. The isolation of polynucleotides encoding a desired FAE1 is described in detail below.

#### Polynucleotides encoding FAE1

The Example section below, which describes the isolation and characterization of an *FAE1* gene in *Arabidopsis* is exemplary of a general approach for isolating genes of the invention. Isolation of this gene allows one of skill to readily isolate homologous genes in *Arabidopsis* and other plant species. The isolated genes can then be used to construct recombinant vectors for altering *FAE1* gene expression in transgenic plants.

Generally, the nomenclature and the laboratory procedures in recombinant DNA technology described below are those well known and commonly employed in the art. Standard techniques are used for cloning, DNA and RNA isolation, amplification and purification. Generally enzymatic reactions involving DNA ligase, DNA polymerase, restriction endonucleases and the like are performed according to the manufacturer's specifications. These techniques and various other techniques are generally performed according to Sambrook et al., *Molecular Cloning - A Laboratory Manual*, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, (1989).

The isolation of *FAE1* genes may be accomplished by a number of techniques. For instance, transposon tagging of an *FAE1* gene can assist in the isolation of the relevant gene. Transposon tagging involves introducing a transposon into the plant which leads to a mutation of the target gene and a detectable phenotypic change in the plant. Using a probe for the transposon, the mutant gene can then be isolated. Using the DNA adjacent to the transposon in the isolated mutant gene as a probe, the normal wild type allele of the target gene can be isolated. See, e.g., Haring, et al., *Plant Mol. Biol.* 16:449-469 (1991) and Walbot, *Ann. Rev. Plant Mol. Biol.* 43:49-82 (1992). As

shown below. a particularly useful transposon tagging system is that disclosed in U.S. Patent No. 5,013,658.

An alternative method uses oligonucleotide probes to identify the desired gene in a cDNA or genomic DNA library. To construct genomic libraries, large  
5 segments of genomic DNA are generated by random fragmentation, e.g. using restriction endonucleases, and are ligated with vector DNA to form concatemers that can be packaged into the appropriate vector. To prepare a cDNA library, mRNA is isolated from the desired organ, such as a seed, and a cDNA library which contains the *FAEI* gene transcript is prepared from the mRNA. Alternatively, cDNA may be prepared  
10 from mRNA extracted from other tissue types (organs) in which *FAEI* genes or homologs are expressed such as seeds, fruits, leaves, stems, and roots.

The cDNA or genomic library can then be screened using a probe based upon the sequence of a cloned *FAEI* gene such as that shown in SEQ. ID. No. 1. Probes may be used to hybridize with genomic DNA or cDNA sequences to isolate  
15 homologous genes in the same or different plant species. The use of such hybridization techniques for identifying homologous genes is well known in the art and need not be described further.

Alternatively, polynucleotides may be synthesized by well-known techniques as described in the technical literature. See, e.g., Carruthers et al., *Cold Spring Harbor Symp. Quant. Biol.* 47:411-418 (1982), and Adams et al., *J. Am. Chem. Soc.* 105:661 (1983). Double stranded DNA fragments may then be obtained either by  
20 synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

The isolated sequences prepared as described herein, can be used in a number of techniques to suppress endogenous *FAEI* gene expression (*i.e.*, to inhibit elongation of C18 FAs to C20 and C22). For instance, antisense technology can be conveniently used to inhibit *FAEI* gene expression. To accomplish this, a nucleic acid segment from the desired gene is cloned and operably linked to a promoter such that the  
25 antisense strand of RNA will be transcribed. The construct is then transformed into plants and the antisense strand of RNA is produced. In plant cells, it has been suggested that antisense RNA inhibits gene expression by preventing the accumulation of mRNA  
30

which encodes the enzyme of interest. see. e.g., Sheeny et al., *Proc. Nat. Acad. Sci. USA*, 85:8805-8809 (1988), and Hiatt et al., U.S. Patent No. 4,801,340.

The nucleic acid segment to be introduced generally will be substantially identical to at least a portion of the endogenous *FAEI* gene or genes to be repressed.

5 The sequence, however, need not be perfectly identical to inhibit expression. The vectors of the present invention can be designed such that the inhibitory effect applies to other proteins within a family of genes exhibiting homology or substantial homology to the target gene. For example, suppression of the *FAEI* gene shown in SEQ. ID. No. 1 may serve to impose the same suppressive effect on other *FAEI* genes with sufficient  
10 identity. Similarly, segments from *FAEI* genes from *Arabidopsis* can be used to inhibit expression of homologous genes in related plant species such as member of the genus *Brassica* or as a means to obtain the corresponding sequences to be used to suppress the endogenous *Brassica* gene.

For antisense suppression, the introduced sequence also need not be full  
15 length relative to either the primary transcription product or fully processed mRNA. Generally, higher homology can be used to compensate for the use of a shorter sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and homology of non-coding segments may be equally effective. Normally, a sequence of between about 30 or 40 nucleotides and about 2000 nucleotides should be used, though a  
20 sequence of at least about 100 nucleotides is preferred, a sequence of at least about 200 nucleotides is more preferred, and a sequence of at least about 500 nucleotides is especially preferred.

Catalytic RNA molecules or ribozymes can also be used to inhibit  
expression of *FAEI* genes. It is possible to design ribozymes that specifically pair with  
25 virtually any target RNA and cleave the phosphodiester backbone at a specific location, thereby functionally inactivating the target RNA. In carrying out this cleavage, the ribozyme is not itself altered, and is thus capable of recycling and cleaving other molecules, making it a true enzyme. The inclusion of ribozyme sequences within antisense RNAs confers RNA-cleaving activity upon them, thereby increasing the activity  
30 of the constructs.

A number of classes of ribozymes have been identified. One class of ribozymes is derived from a number of small circular RNAs which are capable of self-



with a helper virus (satellite RNAs). Examples include RNAs from avocado sunblotch viroid and the satellite RNAs from tobacco ringspot virus, lucerne transient streak virus, velvet tobacco mottle virus, solanum nodiflorum mottle virus and subterranean clover mottle virus. The design and use of target RNA-specific ribozymes is described in  
5 Haseloff et al. *Nature*, 334:585-591 (1988).

Another method of suppression is sense suppression. Introduction of nucleic acid configured in the sense orientation has been recently shown to be an effective means by which to block the transcription of target genes. For an example of the use of this method to modulate expression of endogenous genes see, Napoli et al.,  
10 *The Plant Cell* 2:279-289 (1990), and U.S. Patent No. 5,034,323, 5,231,020, and 5283,184.

Generally, where inhibition of expression is desired, some transcription of the introduced sequence occurs. The effect may occur where the introduced sequence contains no coding sequence *per se*, but only intron or untranslated sequences  
15 homologous to sequences present in the primary transcript of the endogenous sequence. The introduced sequence generally will be substantially identical to the endogenous sequence intended to be repressed. This minimal identity will typically be greater than about 65%, but a higher identity might exert a more effective repression of expression of the endogenous sequences. Substantially greater identity of more than about 80% is  
20 preferred, though about 95% to absolute identity would be most preferred. As with antisense regulation, the effect should apply to any other proteins within a similar family of genes exhibiting homology or substantial homology.

For sense suppression, the introduced sequence, needing less than absolute identity, also need not be full length, relative to either the primary transcription product  
25 or fully processed mRNA. This may be preferred to avoid concurrent production of some plants which are overexpressers. A higher identity in a shorter than full length sequence compensates for a longer, less identical sequence. Furthermore, the introduced sequence need not have the same intron or exon pattern, and identity of non-coding segments will be equally effective. Normally, a sequence of the size ranges noted above  
30 for antisense regulation is used.

Isolated sequences prepared as described herein can also be used to introduce *FAEI* expression or to enhance or increase endogenous *FAEI* gene expression (*i.e.*, to increase production of VLCFAs). Where overexpression of the *FAEI* gene is

desired, an *FAEI* gene from a different species may be used to decrease potential sense suppression effects. For instance, the *Arabidopsis FAEI* gene can be used to increase expression in *Brassica*.

One of skill will recognize that the polypeptides encoded by the *FAEI* genes, like other proteins, have different domains which perform different functions. Thus, the *FAEI* gene sequences need not be full length, so long as the desired functional domain of the protein is expressed. Modified protein chains can also be readily designed utilizing various recombinant DNA techniques well known to those skilled in the art and described in detail, below. For example, the chains can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, additions, deletions, and the like. These modifications can be used in a number of combinations to produce the final modified protein chain.

To use isolated *FAEI* sequences in the above techniques, recombinant DNA vectors suitable for transformation of plant cells are prepared. Techniques for transforming a wide variety of higher plant species are well known and described in the technical and scientific literature. See, for example, Weising et al. *Ann. Rev. Genet.* 22:421-477 (1988). A DNA sequence coding for the desired *FAEI* polypeptide, for example a cDNA sequence encoding a full length protein, will preferably be combined with transcriptional and translational initiation regulatory sequences which will direct the transcription of the sequence from the *FAEI* gene in the intended tissues of the transformed plant.

For example, for overexpression, a plant promoter fragment may be employed which will direct expression of *FAEI* in all tissues of a regenerated plant. Such promoters are referred to herein as "constitutive" promoters and are active under most environmental conditions and states of development or cell differentiation. Examples of constitutive promoters include the cauliflower mosaic virus (CaMV) 35S transcription initiation region, the 1'- or 2'- promoter derived from T-DNA of *Agrobacterium tumefaciens*, and other transcription initiation regions from various plant genes known to those of skill.

Alternatively, the plant promoter may direct expression of the *FAEI* gene in a specific tissue or may be otherwise under more precise environmental or developmental control. Such promoters are referred to here as "inducible" promoters.

Examples of environmental conditions that may effect transcription by inducible promoters include anaerobic conditions, elevated temperature, or the presence of light.

Examples of promoters under developmental control include promoters that initiate transcription only in certain tissues, such as fruit, seeds, or flowers. For example, the use of a napin promoter of *Brassica napus* (Lee et al. *Proc. Natl. Acad. Sci. USA* 88:6181-6185 (1991)) or the promoter from the *Arabidopsis FAE1* gene can direct expression of the *FAE1* polypeptide in seed.

If proper polypeptide expression is desired, a polyadenylation region at the 3'-end of the *FAE1* coding region should be included. The polyadenylation region can be derived from the natural gene, from a variety of other plant genes, or from T-DNA.

The vector comprising the sequences from an *FAE1* gene will typically comprise a marker gene which confers a selectable phenotype on plant cells. For example, the marker may encode biocide resistance, particularly antibiotic resistance, such as resistance to kanamycin, G418, bleomycin, hygromycin, or herbicide resistance, such as resistance to chlorosulfuron or Basta.

Such DNA constructs may be introduced into the genome of the desired plant host by a variety of conventional techniques. For example, the DNA construct may be introduced directly into the genomic DNA of the plant cell using techniques such as electroporation and microinjection of plant cell protoplasts, or the DNA constructs can be introduced directly to plant tissue using ballistic methods, such as DNA particle bombardment. Alternatively, the DNA constructs may be combined with suitable T-DNA flanking regions and introduced into a conventional *Agrobacterium tumefaciens* host vector. The virulence functions of the *Agrobacterium tumefaciens* host will direct the insertion of the construct and adjacent marker into the plant cell DNA when the cell is infected by the bacteria.

Microinjection techniques are known in the art and well described in the scientific and patent literature. The introduction of DNA constructs using polyethylene glycol precipitation is described in Paszkowski et al. *Embo J.* 3:2717-2722 (1984). Electroporation techniques are described in Fromm et al. *Proc. Natl. Acad. Sci. USA* 82:5824 (1985). Ballistic transformation techniques are described in Klein et al. *Nature* 327:70-73 (1987).

*Agrobacterium tumefaciens*-mediated transformation techniques, including disarming and use of binary vectors, are well described in the scientific literature. See,

for example Horsch et al. *Science* 233:496-498 (1984), and Fraley et al. *Proc. Natl. Acad. Sci. USA* 80:4803 (1983).

Transformed plant cells which are derived by any of the above transformation techniques can be cultured to regenerate a whole plant which possesses the transformed genotype and thus the desired *FAEI*-controlled phenotype. Such regeneration techniques rely on manipulation of certain phytohormones in a tissue culture growth medium, typically relying on a biocide and/or herbicide marker which has been introduced together with the *FAEI* nucleotide sequences. Plant regeneration from cultured protoplasts is described in Evans et al., *Protoplasts Isolation and Culture, Handbook of Plant Cell Culture*, pp. 124-176, MacMillan Publishing Company, New York, 1983; and Binding, *Regeneration of Plants, Plant Protoplasts*, pp. 21-73, CRC Press, Boca Raton, 1985. Regeneration can also be obtained from plant callus, explants, organs, or parts thereof. Such regeneration techniques are described generally in Klee et al. *Ann. Rev. of Plant Phys.* 38:467-486 (1987).

The methods of the present invention are particularly useful for incorporating the *FAEI* genes into transformed plants in ways and under circumstances which are not found naturally. In particular, the *FAEI* polypeptides may be expressed at times or in quantities which are not characteristic of natural plants.

One of skill will recognize that after the expression cassette is stably incorporated in transgenic plants and confirmed to be operable, it can be introduced into other plants by sexual crossing. Any of a number of standard breeding techniques can be used, depending upon the species to be crossed.

The effect of the modification of *FAEI* gene expression is conveniently detected by analyzing FA content of plant material from the desired plant. Briefly, lipids are extracted from the plant material (e.g., seeds), FAs are cleaved from the triacylglycerol, and analyzed by gas chromatography as described for instance in James and Dooner *Theor. Appl. Genet.* 80:241-245 (1990). In addition, antisense or sense suppression of the endogenous gene can be detected by reduction of mRNA levels as measured by, for instance, Northern blots.

Plant suppressants of the invention have lower levels of erucic acid less than about 2% (of total FA seed content), preferably lower than about 1%, more preferably lower than about 0.5%, and most preferably lower than about 0.1%. Overexpressing plants of the invention have levels of erucic acid substantially higher than

the corresponding untransformed plant. e.g., at least 10% higher. preferably at least 20% higher. more preferably at least 30% higher. and most preferably at least 40% or 50% higher. Preferred resultant levels of erucic acid in overexpressing *Brassica* plants of the invention are at least about 40% (of total FA seed content), preferably at least about  
5 50%. more preferably at least about 60%. Even higher levels may be obtained with other oil producing plants. e.g., in order of increasing preference at least about 70%, 80% or 90%. Erucic acid may be extracted from overexpressing plants of the invention using known methods. See Salunkhe and Desai (1986), supra.

The following Examples are offered by way of illustration, not limitation.

#### Example 1

##### Isolation and sequencing of the *FAEI* gene from *Arabidopsis*

5       The strategy used to isolate FA biosynthetic genes from *Arabidopsis* is illustrated in Figure 1. In this work, transposon tagging was done with the autonomous maize element *Ac*.

##### A. Mutant creation and *Ac* transformation

##### 1. Mutant Formation

10       A collection of mutants was induced and characterized in order to genetically define loci that affect FA composition in *Arabidopsis* seeds (obtainable from the *Arabidopsis* Biological Resource Center at Ohio State University) as described by James and Dooner (1990), *supra*.

##### 2. *Ac* transformation

15       68 independent single locus *Arabidopsis* transformants carrying *Ac* in the T-DNA were generated using the methods of Keller *et al.*, *Genetics*, 131:44-459 (1992). This number provides >95% confidence that any gene in the *Arabidopsis* genome will be no farther than 15 cM from an introduced *Ac*, assuming random integration of the T-DNA in the genome and a <600 cM genetic map (Koorneeff *et al.*, in *Genetic Maps*, S.J. O'Brien ed. (Cold Spring Harbor Press, Cold Spring Harbor (1992)). In  
20       *Arabidopsis*, as well as in maize and other organisms, transposons of the *Ac/Ds* family transpose preferentially to sites linked to the donor site (Keller *et al.*, *Theor. Appl. Genet.* 86:585-588 (1993)). Therefore, in order to tag a specific gene, it is preferable to initiate the tagging experiment with an *Ac* (or *Ds*) element linked to the gene of interest.  
25       This approach, referred to as directed tagging, requires mapping of the T-DNAs relative to the target loci. Scoring for the presence or absence of the T-DNA was facilitated by the *Hyg-R* (hygromycin resistance) transformation marker. The number of plants with transposed *Ac* (*trAc*) elements required to isolate a specific FA mutation was therefore greatly reduced relative to that required in a random transposon tagging approach.

##### 30       3. T-DNA localization (mapping)

      Of twenty-four T-DNAs localized to one of the five *Arabidopsis* chromosomes, three were linked to *FAEI*. In transformants K805, B116, and C231, the T-DNAs were located respectively, 15, 22, and 40 cM from *FAEI*. *FAEI* is loosely

linked to the RFLP marker 518 which was mapped to chromosome 4 by Chang *et al.*, *Proc. Natl. Acad. Sci. USA* 85:6856-6860 (1988). Linkage of the B116 T-DNA to marker 518 was confirmed by a bulked segregant analysis procedure (Michelmore *et al.*, *Proc. Natl. Acad. Sci. USA* 88:9828-9832 (1991)) in which paired DNA samples obtained from pooled homozygous *Hyg-R/Hyg-R* and *+/+* segregants from a *Hyg-R/+* (WS x Columbia) heterozygote were scored for segregating RFLPs. A chromosomal location was assigned to 24 single locus, *Ac*-containing T-DNA insertions by the combination of two-point crosses and bulked segregant analyses.

#### 4. Make up of T-DNA

In the pJ4404 construct used in the derivation of transgenic line B116, *Ac* lies in the 5' untranslated region of the *SPT* (streptomycin phosphotransferase) gene (Jones *et al.*, *Science* 244:204-207 (1989); Keller *et al.*, *Plant Mol. Biol.* 21:157-170 (1993)). Somatic excisions of *Ac* during the development of the cotyledons can be detected as green sectors on a white background in *Arabidopsis* seedlings germinated in streptomycin. Germinal excisions of *Ac* give rise to *SPT'* fully green seedlings, about half of which carry a *trAc* element somewhere in the genome (Dean *et al.*, *The Plant Journal* 2:69-81 (1992); Keller *et al.*, *Genetics* 131:449-459 (1992)). Therefore, *SPT::Ac* constitutes an efficient marker for selecting plants that have undergone transposition.

Germinal selections recovered from one plant may derive from a common premeiotic event and carry the same transposed element. To avoid extensive sampling of duplicates for the same transposition event, in general, no more than four green seedling selections from any one plant were transferred to the greenhouse.

#### B. Identification of a new *fae1* mutation

##### 1. Isolation and characterization of germinal selections

Green *SPT'* seedling were selected on streptomycin (Jones *et al.*, (1989), *supra*) grown to maturity in the greenhouse, and the FA composition of their seeds was analyzed by gas chromatography (GC) as described previously (James and Dooner (1990), *supra*). Because *fae1* and several other mutations affecting seed FA composition are codominant (James and Dooner (1990); Lemieux *et al.*, (1990), *supra*) they can be identified in the heterozygous condition, a clear advantage when dealing with a difficult phenotype, such as a chromatographic profile. Selections were made from lines in which

*Ac* was either linked or unlinked to *FAE1*. Table 1 gives the number of *SPT*' selections analyzed, the number of plants which produced them, and the location of *Ac* relative to *FAE1* in each line. Also given are estimates of the minimum and maximum number of independent *Ac* reinsertions screened, assuming a 50% *Ac* reinsertion frequency (Keller *et al.* (1992), *supra*). The minimum number, i.e., the number screened if all the green sibs were derived from the same transposition event, corresponds to half the number of parent plants which produced green seedlings. The maximum number, i.e., the number screened if all the sibs resulted from independent transposition events, corresponds to half the number of selections analyzed. The actual number of independent *Ac* reinsertions assayed lies somewhere between the two values since both clonal and single *Ac* transposition events can be recovered from the same plant (Keller *et al.* 1992).



Table 1. SPT' revertants analyzed for fatty acid composition

5	T-DNA line	<i>Ac-Fuel</i> linkage	No. <u>SPT'</u> selections analyzed	No. plants producing selections	Min.- Max.	
					No. independent <i>Ac</i> reinsertions <sup>a</sup>	
10	K805	15 cM	1522	660	330-761	
	B116	22 cM	721	272	136-361	
	Subtotal	Linked	2243	932	466-1122	
15						
	C201	Unlinked		2107	324	162-1054
	B246	Unlinked		680	227	114-340
20	A018	Unlinked		273	91	45-136
	Subtotal	Unlinked		3060	642	321-1530

25 a Assumptions: 50% reinsertions among SPT' selections. Minimum, all selections clonal. Maximum, all selections independent.

2. Identification of *Fael-G309*

A total number of 721 *SPT'* selections from B116 were analyzed. Plants from the B116 line produced an average of >1% green selections per plant, but the percentages varied greatly from plant to plant. One selection, G309, produced seed with the reduced 20:1 content typical of an *FAE1/fael* heterozygote. Upon selfing, one quarter of its progeny had a more extreme seed FA composition, indistinguishable from that of the EMS- induced mutant *fael-2* (referred to as 9A1 in James and Dooner, 1990). The new mutation was tested for allelism with *fael-2*. Because the mutants failed to complement, the provisional designation *fael-G309* was assigned to the new mutant. The FA compositions of *fael-G309* homozygous, heterozygous and wild-type seeds are presented in Table 2A; those of *fael-2* and *fael-2/fael-G309* seeds, in Table 2B.

Table 2. Percent fatty acid composition of seeds from various genotypes

Sample	16:0	18:0	18:1	18:2	18:3	20:0	20:1	22:1
--------	------	------	------	------	------	------	------	------

## A.

Wild type (+/+)	5.1	1.6	10.9	31.2	20.6	1.5	24.2	2.3
-----------------	-----	-----	------	------	------	-----	------	-----

<u>fael-G309/+</u>	5.9	2.2	19.1	33.6	21.2	0.9	14.5	1.0
--------------------	-----	-----	------	------	------	-----	------	-----

<u>fael-G309/fael-G309</u>	6.4	2.4	26.1	38.7	25.3	0.4	0.1	0.0
----------------------------	-----	-----	------	------	------	-----	-----	-----

## B.

<u>fael-2/fael-2</u>	8.5	2.9	30.8	30.1	26.9	0.0	0.4	0.0
----------------------	-----	-----	------	------	------	-----	-----	-----

<u>fael-2/fael-G309</u>	6.6	2.5	32.9	33.4	22.8	0.6	0.7	0.0
-------------------------	-----	-----	------	------	------	-----	-----	-----

C. Evidence that the new *fael* mutation is tagged by *Ac*

1. Cosegregation of the *fae* mutant phenotype with an *Ac*- hybridizing band

DNA analysis of the *fael*-G309 derivative showed the presence of a new *Ac*-hybridizing band. DNA extraction and DNA blot analysis were performed as previously described (Keller et al. (1992), *supra*). The joint segregation of this new *Ac* band with the *fael* mutation was tested in the self progeny of an *fael*-G309/*Fael* heterozygote. Segregating individuals were scored as *Fael*/*Fael*, *Fael*/*fael* or *fael*/*fael* by GC analysis of their seed FA composition and as *Ac*(-) or +/+ by DNA gel blot analysis. Thus, six genotypic classes could be distinguished. DNA from 54 individuals was digested with HindIII and hybridized with a probe from the 5' end of *Ac* (Kunze et al., *EMBO J.* 6:1555-1563 (1987)). Results of these hybridizations showed two *Ac*-hybridizing bands segregating in the progeny, a 3.3-kb and a 2.4-kb band. The former represents the newly transposed *Ac* (*trAc*) and the latter, the *Ac* at the *SPT::Ac* resident site in the T-DNA (the selfed parent was the original G309 green selection, *SPT*'/*SPT::Ac*).

The results of the cosegregation analysis are presented in Table 3A. All of the individuals carrying the new *trAc* were either homozygous or heterozygous for the new *fael* mutation. Conversely, all of the individuals that lacked the *trAc* were wild-type. Therefore, no recombinants were recovered (linkage  $X^2=54$ ,  $P<0.001$ ).

DNA from the region flanking the 5' end of the *trAc* in the *fael*-*ml* (*Ac*) mutant was generated for cloning by inverse PCR (Ochman et al., *Genetics* 120:621-623 (1988)). DNA was obtained from progeny of *fael*-G309 that contained the 3.3-kb *Ac*-hybridizing HindIII fragment that cosegregated with the *fael* phenotype, but lacked the smaller 2.4-kb *Ac*-hybridizing band. Approximately 0.5 ug of genomic DNA was digested with HindIII and ligated overnight at 16° C under dilute conditions (200 ul reaction volume) to favor circularization of the HindIII fragments. Primers FL125, oriented outward from the 5' end of *Ac* (CGGTTATACGATAACGGTCG) and JK30, just 5' from the first HindIII site in *Ac* (GTACGATGAAGTGGTTAGCC) were used to amplify the 1.5-kb of genomic DNA flanking the 5' end of the *trAc*.

This flanking DNA was used to reprobe the same DNA gel blots. As expected, the new probe detected the same 3.3-kb *Ac*-homologous fragment and, in addition, a new fragment of about 1.8 kb. If *Ac* had, in fact, tagged the *FAEI* gene, all the segregating *fael* mutant plants should be homozygous for the 3.3-kb band, all

*Fael/fael* plants should be heterozygous for the 3.3-kb and the 1.8-kb band and all wild-type plants should be homozygous for the 1.8-kb band. The results of the analysis are presented in Table 3B. 53 of the 54 segregants fit the expectation. The one exception (segregant #5) was heterozygous for the 3.3-kb *irAc* band. There are two plausible explanations for this exception. (1) The new *fae* mutation is not tagged by the *irAc*, but is closely linked to it, and this individual is a recombinant between the *fael* mutation and the *irAc*. (2) The new *fael* mutant is tagged by the *irAc* and this individual is the product of an *Ac* excision that did not restore gene function. Segregant #5 also had a new *Ac*-hybridizing band, which was absent in the other 53 sibs (data not shown), an observation suggesting that it might have originated by secondary transposition of *Ac*.

Table 3. Segregation data for the self-progeny of a Fael/fael; trAc/+ heterozygote

5

A. DNA from segregants scored with an Ac probe

10

<u>FAEI</u> genotype	<u>trAc</u> genotype		Total
	<u>trAc</u> /(-)	+/+	
<u>Fael/Fael</u>	0	9	9
<u>Fael/fael</u>	29	0	29
<u>fael/fael</u>	16	0	16
	45	9	54

20

B. DNA from segregants scored with probes for Ac and the flanking DNA

25

30

<u>FAEI</u> genotype	<u>trAc</u> genotype			Total
	<u>trAc</u> / <u>trAc</u>	<u>trAc</u> /+	+/+	
<u>Fael/Fael</u>	0	0	9	9
<u>Fael/fael</u>	0	29	0	29
<u>fael/fael</u>	15	1	0	16
	15	30	9	54

35

40

## 2. Reversion of the *fae1* mutant

To confirm that the *fae1-G309* mutation was tagged by *Ac*, progeny of mutant plants were screened for putative revertants, i.e., individuals with an intermediate seed FA composition, which could then be examined for excision of *Ac* from the cloned DNA. A total of 1052 offspring from four *fae1-G309* plants were screened and three putative revertants to wild-type were identified on the basis of an intermediate seed FA composition, typical of *Fae1/fae1* heterozygotes (12-15% 20:1). Using DNA gel blot analysis, all three exceptions were found to be heterozygous for the 3.3-kb band in the original mutant allele and a 1.8-kb wild-type-sized band. This is the result expected if these individuals originated from *Ac* excision events that restored gene function.

The DNA around the *rrAc* insertion site in the wild-type progenitor allele, the *fae1-G309* mutant, and the three putative revertants was amplified by the polymerase chain reaction procedure described in Saiki (1990) and sequenced. DNA was sequenced with either the Sequenase kit (U.S. Biochemical) or the fmol kit (Promega) following the recommendations of the manufacturers. A comparison of the sequences is presented in Figure 2.

In general, when *Ac* excises it leaves behind an 8 bp "footprint" with occasional deletion or addition of bases to restore the reading frame number (a multiple of three). However, somewhat unexpectedly, the DNA sequences of the three putative revertants were identical to that of the wild-type progenitor. The sequence of the putative *FAE1* protein around the site of insertion of *Ac* may be intolerant of amino acid changes, so that only the rare events that restore not just the correct reading frame but the original sequence are selected as revertants. If so, segregant #5, the exception from the cosegregation analysis (Table 3B) would represent an *Ac* excision event that did not restore the original amino acid sequence and, thus, failed to restore gene function. The DNA sequence of segregant #5 (Figure 2) revealed an 8bp footprint at the *Ac* excision site, indicating that this exception had originated by an *Ac* excision that created a frame-shift mutation and knocked out gene function.

Thus, the analysis of revertants and of the one null exception in the cosegregation test confirms that the *fae1-G309* mutant arose by insertion of *Ac* into the *FAE1* gene, that it is unstable, and that it can give rise to new alleles at the *FAE1* locus. Hence, it has been given the official designation *fae1-m1(Ac)* to denote that it is the first

mutable allele of the *FAEI* locus isolated and that it arose by insertion of the transposon *Ac*.

D. Function of the *FAEI* gene in *Arabidopsis*

5 1. Expression of *FAEI* in developing seed

Since VLCFAs accumulate in seeds, but not in leaves of *Arabidopsis* (Lemieux *et al.* (1990), *supra*), *FAEI* should be expressed preferentially in seeds. Expression of the *FAEI* gene was assayed by gel blot analysis of RNA from several tissues: leaf, immature seeds and immature siliques plus seeds (pools of ~ 1 week and of  
10 2-3 week old siliques). RNA from various *Arabidopsis* tissues (developing siliques, leaves, and immature seed ) was isolated by the phenol-SDS method described in Napoli *et al.*, *The Plant Cell* 2:279-289 (1990), separated by formaldehyde agarose gel electrophoresis and blotted to Duralon-UV membranes (Stratagene). *FAEI* transcripts were found to accumulate in siliques containing developing seeds and seeds, but not in  
15 leaves.

2. Isolation and sequencing of an *FAEI* cDNA clone

The 1.5 Kb *FAEI* IPCR fragment was used as a probe to isolate 2 lambda clones from a genomic library of DNA from *Arabidopsis*, ecotype Ws, partially digested with *Sau* 3A and ligated into lambda-DASH (Stratagene) using procedures recommended  
20 by the manufacturer. The *FAEI* gene was localized within the lambda clones by restriction analysis and by using subcloned regions as probes against silique RNA.

Poly(A) RNA was isolated from 1 g of 2-3 week old green siliques using a Poly ATract system 1000 kit (Promega), following the instructions of the manufacturer. An immature silique cDNA library was made from polyA RNA using the lambda-Zap  
25 cDNA synthesis kit (Stratagene), following the instructions provided by the manufacturer. A 1.0 Kb *Bgl*II to *Hind*III fragment from the 5' end of the *FAEI* gene and a 700bp *Bst*XI to *Eco*RI fragment from the middle of the *FAEI* gene were used as probes to screen this cDNA library. A cDNA clone containing a 1.7-kb insert, roughly the size of the *FAEI* transcript was isolated and sequenced. DNA was sequenced with  
30 either the Sequenase kit (U.S. Biochemical) or the fmol kit (Promega) following the recommendations of the manufacturers.

The cDNA nucleotide sequence is provided in SEQ. ID. No. 1. It matches the sequence of the genomic DNA throughout its length, indicating that there



are no introns in this segment of the *FAEI* gene. The cDNA contains a long open reading frame (ORF), but appears to be short of full length. If the ATG located in the corresponding *FAEI* genomic sequence 20 nucleotides upstream from the 5' end of the cDNA is the initiation codon, the extended open reading frame encodes a protein of 507 amino acids with a predicted sequence as shown in SEQ. ID. No. 2. A diagram of the structure of the *FAEI* genomic region, including the location of the cDNA and of the *Ac* insertion site in *fael-m1(Ac)* is shown in Figure 3.

## Example 2

Cloning of *FAEI* c-DNA from *Brassica napus* immature embryos

A c-DNA library from *B. napus* (var. Bridger) embryos was constructed in the vector lambda Uni-Zap XR (Stratagene) from 5 $\mu$ g of polyA RNA following the instructions of the manufacturer. The library was screened for *FAEI* clones as follows. A total of 120,000 plaques were screened in duplicate using, respectively, the 3' and 5' ends of the *FAEI* genomic fragments from *Arabidopsis thaliana*. Hybridization and washes were done at 60°C. The wash solution was 0.2X SSC and 1% SDS. From the primary screen, a total of 14 potential *FAEI* clones hybridizing to either the 3' end probe only or both the 3' and 5' ends were picked for further purification. On secondary screening, four of the original 14 gave positive signals to both probes. Those four clones were purified to homogeneity. They were designated as 3B, 4A, 11A and 12B.

The c-DNA fragments from the four clones were excised from the lambda Zap (Stratagene) vector as plasmids and DNA preps were made. They were characterized with respect to restriction digests, PCR and partial sequencing. HindIII restriction digests of the four clones and of an *Arabidopsis* c-DNA control showed that the four *Brassica* clones were different from the *Arabidopsis* one. While the *Arabidopsis* clone gave rise to two HIII fragments, three of the *Brassica* clones yielded only one HIII fragment. *Brassica* clone 11A gave two HIII fragments, but the fragment sizes were different from those produced by the *Arabidopsis FAEI* cDNA clone. Restriction with HIII and XhoI showed that clone 12B was different from 3A and 4A. PCR amplification of 3A and 11A with primers based on the *Arabidopsis FAEI* genomic sequence produced different sized bands, confirming the nonidentity of these clones. Partial sequences of 3A and 11A showed that they were 95% homologous at both the 3' and 5' ends of the nucleotide sequence. Sequence I.D. No. 3 is a partial sequence of the coding region of clone 4A, starting with a base pair which is approximately 900 bp downstream of the translation start. Sequence I.D. No. 4 shows the corresponding amino acid sequence. Figure 4 shows a comparison of this amino acid sequence with a corresponding sequence from the *Arabidopsis* protein (Seq. I.D. No. 2). This comparison revealed 94% similarity between the two proteins.

## Example 3

Suppression of *FAEI* expression in *Brassica*

The *Fael* cDNA, described in Example 1 (SEQ I.D. No. 1) of length 1639 bp, is excised from the vector as an EcoRI/XhoI fragment and cloned into plasmid p2104-CABL (Harpster et al., *Mol. Gen. Genet.* 212: 182-190) that has been digested with Nco I and Bam HI. All restriction sites are treated with Klenow to blunt end them. Standard molecular biology techniques are used (*see, e.g., Sambrook et al., supra*). Plasmid p2104-CABL has 1.34 kb of CaMV 35S promoter sequence, 60 bp of petunia CABL22 untranslated leader sequence and 260 bp of NOS 3' polyadenylation sequence. With this  
5 ligation p35S-*Fael*-NOS 3' is selected with *Fael* in the transcriptional orientation for sense suppression and p35S-*Fael*-NOS 3' is selected for antisense suppression.  
10

The gene fusions in p35S-*Fael*-NOS 3' and p35S-*leaF*-NOS 3' are excised as Bgl II/ Hind III fragments and cloned into the binary vector WTT2143 using standard techniques (Sambrook et al., *supra*). WTT2143 has a p2'-HPT-NOS 3' fusion for  
15 selection of transformed plants and a tetracycline resistance gene for selection of the plasmid in *E. coli* and *Agrobacterium*.

The resulting binary vectors are mobilized into *Agrobacterium tumefaciens*, strain LBA4404 by conjugation (Herrera-Estrella and Simpson in C. H. Shaw (Ed) *Plant Molecular Biology* pp. 131-158.(1988)).

20 The sense and/or antisense *Fael* binary constructs are introduced from the *Agrobacterium* strain carrying them into 5-day old hypocotyl sections of *Brassica napus* cv. Westar by cocultivation. Transformed shoots are selected in the presence of hygromycin B. The *Agrobacterium* is selected against with 500 mg/ml cefotaxim and the transformed tissue is allowed to callus in the presence of 20 mg/ml hygromycin B, 3%  
25 sucrose, 0.2 mg/L 2,4 D and 3 mg/L kinetin. Shoots are stimulated on the transformed callus using medium containing 2.5 uM IBA, 5 mg/L AgNO<sub>3</sub>, 15 uM thidiazuron and 20 mg/L hygromycin B. The shoots are normalized in medium containing 0.125 mg/L BAP and 500 mg/L Geopen, and then rooted in the absence of hormones and hygromycin B.

Transformed plants are grown to maturity and allowed to self-pollinate.  
30 The resulting seeds are analyzed by gas chromatography (as described in Example 1 and references therein) to select for plants with reduced erucic acid content of less than 1% (of total FA content).

**Example 4****Overexpression of *FAEI* in *Brassica napus***

Overexpression of *Fael* is obtained using the steps of Example 3 with modifications as stated below. The desired outcome is that the seeds of the transgenic plants should have a higher erucic acid content than seeds of the untransformed controls. The constructions in Example 3 do not give translationally active gene products. Translational activity is important for overexpression. Proper design of the p35S-*Fael*-NOS 3' fusion is achieved by using standard oligonucleotide mutagenesis techniques (Sambrook *et al.*, *supra*) to create an Nco I site at the starting methionine in the genomic clone of *Fael* and then fusing this and the bulk of the gene from the cDNA to the 35S promoter at the Nco I site in plasmid 2104-CABL. After transformation, plant growth, self-pollination and gas chromatograph analysis, as called for in Example 3, plants are selected with erucic acid content of at least 40% (of total FA content).

The above examples are provided to illustrate the invention but not to limit its scope. Other variants of the invention will be readily apparent to one of ordinary skill in the art and are encompassed by the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference.

## Sequence Listing

SEQ. ID. No. 1 (Nucleotide sequence of *FAE1* from *Arabidopsis*)

Cdna-Con.Seq Length: 1641

5  
1 ATGACGTCCG TTAACGTTAA GTCCTTTAC CGTTACGTCT TAACCAACTT  
51 TTCAACCTC TGTTGTTC CGTTAACGGC GTTCCTCGCC GGAAAAGCCT  
101 CTCGGCTTAC CATAAACGAT CTCCACAACCT TCCTTTCCTA TCTCCAACAC  
151 AACCTTATAA CAGTAACCTT ACTCTTTGCT TTCACTGTTT TCGGTTTGGT  
10 201 TCTCTACATC GTAACCCGAC CCAATCCGGT TTATCTCGTT GACTACTCGT  
251 GTTACCTTCC ACCACCGCAT CTCAAAGTTA GTGTCTCTAA AGTCATGGAT  
301 ATTTTCTACC AAATAAGAAA AGCTGATACT TCTTCACGGA ACGTGGCATG  
351 TGATGATCCG TCCTCGCTCG ATTTCTGAG GAAGATTCAA GAGCGTTCAG  
401 GTCTAGGTGA TGAGACGTAC AGTCCTGAGG GACTCATTCA CGTACCACCG  
15 451 CGGAAGACTT TTGCAGCGTC ACGTGAAGAG ACAGAGAAGG TTATCATCGG  
501 TGCGCTCGAA AATCTATTCT AGAACACCAA AGTTAACCTT AGAGAGATTG  
551 GTATACTTGT GGTGAACCTA AGCATGTTTA ATCCAACCTC TTCGCTATCC  
601 GCTATGGTCG TTAATACTTT CAAGCTCCGA AGTAACATCA AAAGCTTTAA  
651 TCTAGGAGGA ATGGGTTGTA GTGCTGGTGT TATTGCCATT GATTGGCTA  
20 701 AAGACTTGTT GCATGTTTAT AAAACACTT ATGCTCTTGT GGTGAGCACT  
751 GAGAACATCA CACAAGGCAT TTATGCTGGA GAAAATAGAT CAATGATGGT  
801 TAGCAATTGC TTGTTTCGTG TTGGTGGGGC CGCGATTTTG CTCTCTAACA  
851 AGTCGGGAGA CCGGAGACGG TCCAAGTACA AGCTAGTTCA CACGGTCCGA  
901 ACCCATACTG GAGCTGATGA CAAGTCTTTT CGATGTGTGC AACAAGAAGA  
25 951 CGATGAGAGC GGCAAAATCG GAGTTTGTCT GTCAAAGGAC ATAACCAATG  
1001 TTGCGGGGAC AACACTTACG AAAAATATAG CAACATTGGG TCCGTTGATT  
1051 CTTCTTTTAA GCGAAAAGTT TCTTTTTTTC GCTACCTTCG TCGCCAAGAA  
1101 ACTTCTAAAG GATAAAATCA AGCATTACTA TGTTCGGAT TTCAAGCTTG  
1151 CTGTTGACCA TTTCTGTATT CATGCCGGAG GCAGAGCCGT GATCGATGAG  
30 1201 CTAGAGAAGA ACTTAGGACT ATCGCCGATC GATGTGGAGG CATCTAGATC  
1251 AACGTTACAT AGATTGGGA ATACTTCATC TAGCTCAATT TGGTATGAAT  
1301 TAGCATACAT AGAGGCAAAG GGAAGAATCA AGAAAGGGAA TAAAGCTTGG  
1351 CAGATTGCTT TAGGATCAGG GTTAACTCT AATAGTCCG TTTGGGTGGC  
1401 TCTACGCAAT GTCAAGGCAT CGGCAAATAG TCCTTGGCAA CATTGCATCG  
35 1451 ATAGATATCC GGTAAAATT GATTCTGATT TGTCAAAGTC AAAGACTCAT  
1501 GTCCAAAACG GTCGGTCTTA ATTTGATGTA TCTGAGTGCC AACGTTTACT  
1551 TTGTCTTTCC TTTCTTTTAT TGGTTATGAT TAGATGTTTA CTATGTTCTC  
1601 TCTTTTTCGT TATAAATAAA GAAGTTCAAT TCTTCTATAA A

## SEQ. ID. No. 2 (Amino acid sequence of FAE1 protein)

Length: 506

```
5      1  MTSVNVKLLY RYVLTNFFNL CLFPLTAFLA GKASRLTIND LHNFLSYLQH
      51  NLITVTLLFA FTVFGLVLYI VTRPNPVYLV DYSCYLPPPH LKVSVSKVMD
     101  IFYQIRKADT SSRNVACDDP SSLDFLRKIQ ERSGLGDETY SPEGLIHVPP
     151  RKTFAASREE TEKVIIGALE NLFENTKVNP REIGILVVNS SMFNPTPSLS
     201  AMVVNTFKLR SNIKSFNLGG MGCSAGVIAI DLAKDLLHVH KNTYALVVST
    10  251  ENITQGIYAG ENRSMMSVNC LFRVGGAAIL LSNKSGDRRR SKYKLVHTVR
     301  THTGADDKSF RCVQQEDDES GKIGVCLSKD ITNVAGTTLT KNIATLGPLI
     351  LPLSEKFLFF ATFVAKLLK DKIKHYYPV FKLAVDHFCI HAGGRAVIDE
     401  LEKNLGLSPI DVEASRSTLH RFGNTSSSSI WYELAYIEAK GRMKKGNKAW
     451  QIALGSGFKC NSAVWVALRN VKASANSPWQ HCIDRYPVKI DSDLSSKSKTH
    15  501  VQNGRS
```

SEQ. ID. No. 3 (partial nucleotide sequence of *B. napus* *FAEI* gene)

Seq Length: 383

```
1  TCGAACGCAT ACCGGAGCTG ACGACAAGTC TTTTcgTTGC GTGCAAcAAG
5  51  GAGACGATGA GAACGGCAAA ATCGGAGTGA GTTTGTCCAA GGACATAACC
101 GATGTTGCTG GTCGAACgGT TAAGAAAAAC ATAGCAACgT TgGGtCCGTT
151 gATTCTTCCG TTAaGCGAGA AACTTCTttt tttCGTTACC TTCATGGGCA
201 AGAAACTTTT CAAAGATAAA ATCAAACATT ACTACGTCCC GGATTTCAAA
251 CTTGCTATTG ACCATTTTTG TATACAaCGG AGCAGAGCcG TGATTGATGT
10 301 GCTAGAGAAG AACCTAGCCC TAGCACCGAT CGATGTAGAG GCATCAAGAT
351 CAACGTTACA TAGATTTGGA AACACTTCAT CTA
```

SEQ. ID. No. 4 (partial amino acid sequence of *B. napus* FAE1 protein)

Length: 127

1 RTHTGADDKS FRCVQQGDDE NGKIGVSLSK DITDVAGRTV KKNIATLGPL  
5 51 ILPLSEKLLF FVTFMGKKLF KDKIKHYYVP DFKLAIDHFC IHRSRAVIDV  
101 LEKNLALAPI DVEASRSTLH RFGNTSS



WHAT IS CLAIMED IS:

1. An isolated DNA construct comprising a polynucleotide sequence of at least about 30 nucleotides from an *FAEI* gene.
- 5 2. The DNA construct of claim 1, wherein the *FAEI* gene is from *Arabidopsis*.
3. The DNA construct of claim 1, wherein the polynucleotide sequence  
10 is substantially identical to a sequence of least about 30 nucleotides from SEQ. ID. No. 1.
4. The DNA construct of claim 1, wherein the polynucleotide sequence is SEQ. ID. No. 1.
- 15 5. The DNA construct of claim 1, wherein the polynucleotide sequence is a full length *FAEI* gene.
6. The DNA construct of claim 1, further comprising a promoter operably linked to the polynucleotide sequence.
- 20 7. The DNA construct of claim 6, wherein the polynucleotide sequence is linked to the promoter in an antisense orientation.
8. The DNA construct of claim 6, wherein the promoter is a plant  
25 promoter.
9. The DNA construct of claim 8, wherein the promoter is a seed-specific promoter.
- 30 10. A transgenic plant comprising a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence of at least about 30 nucleotides from an *FAEI* gene.

11. The transgenic plant of claim 10, wherein the plant promoter is a heterologous promoter.

12. The transgenic plant of claim 10, wherein the polynucleotide  
5 sequence is linked to the promoter in an antisense orientation.

13. The transgenic plant of claim 10, wherein the plant is *Brassica napus*.

10 14. The transgenic plant of claim 10, wherein the *FAEI* gene is from *Arabidopsis*.

15 15. The transgenic plant of claim 10, wherein the polynucleotide sequence is substantially identical to a sequence of at least 30 nucleotides from SEQ. ID. No. 1.

16. The transgenic plant of claim 10, wherein the polynucleotide sequence is SEQ. ID. No. 1.

20 17. A method of modulating fatty acid content in a plant, the method comprising:  
introducing into plant tissue a recombinant expression cassette comprising a plant promoter operably linked to a polynucleotide sequence from an *FAEI* gene;  
regenerating the plant tissue into a whole plant, whereby the regenerated  
25 plant transcribes the polynucleotide sequence; and  
selecting plants having altered fatty acid content.

18. The method of claim 17, wherein the plant tissue is from *Brassica*.

30 19. The method of claim 17, wherein the recombinant expression cassette is introduced into the plant tissue using *Agrobacterium*.

20. The method of claim 17, wherein the polynucleotide sequence is linked to the promoter in an antisense orientation.

21. The method of claim 17, wherein the polynucleotide sequence is  
5 linked to the promoter in a sense orientation.

22. The method of claim 17, wherein the polynucleotide sequence is substantially identical to SEQ. ID. No. 1.


10 23. The method of claim 17, wherein the promoter is a seed-specific promoter.

24. A method of isolating an *FAEI* gene from a plant, the method comprising probing a DNA library prepared from the plant with oligonucleotide probes  
15 comprising a polynucleotide sequence from an isolated *FAEI* gene.

25. The method of claim 24, wherein the DNA library comprises cDNA.

20 26. The method of claim 24, wherein the isolated *FAEI* gene is SEQ. ID. No. 1.

1/3

**FIG. 1.**

2/3

NUCLEOTIDE SEQUENCE OF *FAEI* AROUND THE SITE OF INSERTION OF *Ac*

WILD-TYPE <i>FaeI</i>	GTTGACTACTCGTGTT
<i>faeI-m::Ac</i>	GTTGACTACTCGIACIACIACGCGT
<i>FaeI'</i> REVERTANTS(3)	GTTCAGTACTCGTGTT
<i>faeI</i> SEGREGANT #5	GTTCAGTACTCGIACIACIACGCGT

FIG. 2.




FIG. 3.

3/3

SYMBOL COMPARISON TABLE: GENCOREDISK: [Gcgcore.Data.Rundata]Swgappep.Cmp  
CompCheck: 1254

GAP WEIGHT: 3.000                      AVERAGE MATCH: 0.540  
LENGTH WEIGHT: 0.100                  AVERAGE MISMATCH: -0.396

QUALITY: 169.7                          LENGTH: 128  
RATIO: 1.336                            GAPS: 1  
PERCENT SIMILARITY: 94.488            PERCENT IDENTITY: 85.827

GAP LIMIT ONE: 505                    GAP LIMIT TWO: 126

```

1  RHTGADDKSFRVCVQQGDDENGKIGVSLSKDITDVAGRTVKKNIATLGPL 50
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
300 RHTGADDKSFRVCVQQEDDESCKIGVCLSKDITNVAGTTLTKNIATLGPL 349

51  ILPLSEKLLFFVTFMGKKLFKDKIKGYVVPDFKLAIHFCIH.RSRAVID 99
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
350 ILPLSEKFLFFATFVAKKLLKDKIKHYVVPDFKLAVDHFCHAGGRAVID 399


100 VLEKNLALAPIDVEASRSTLHFRFGNTSS 127
   |||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||:|||||
400 ELEKNLGLSPIDVEASRSTLHFRFGNTSS 427
  
```

FIG. 4.

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/13918

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) : Please See Extra Sheet. US CL : Please See Extra Sheet. According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/6, 172.3, 320.1; 536/23.6, 24.3; 800/205 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS, APS, DIALOG, GENBANK, EMBL search terms: elongase, fae, fae1, vicfa, fatty acid elong7, SEQ ID NO:1		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X, P	The Plant Cell, Volume 7, issued March 1995, James et al, "Directed tagging of the Arabidopsis <i>FATTY ACID ELONGATION1 (FAE1)</i> gene with the maize transposon activator", pages 309-319, see entire document.	1-5, 24-26
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 25 JANUARY 1996		Date of mailing of the international search report 08 FEB 1996
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer P. MOODY  Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet)(July 1992)\*

INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US95/13918

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

C12N 15/10, 15/11, 15/29, 15/52, 15/82; A01H 5/00

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

435/6, 172.3, 320.1; 536/23.6, 24.3; 800/205

Form PCT/ISA/210 (extra sheet)(July 1992)\*